Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period

Driven by Emerging Drug Classes Like TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators

Apr. 13, 2026 at 5:30pm

Got story updates? Submit your updates here. ›

A glowing, neon outline of a human esophagus against a dark background, conceptually representing the internal inflammation and irritation of eosinophilic esophagitis.Innovative therapies targeting the underlying drivers of eosinophilic esophagitis aim to transform the standard of care and provide new hope for patients struggling with this chronic, inflammatory condition.NYC Today

The eosinophilic esophagitis market is witnessing steady growth, primarily driven by increasing awareness leading to standardized diagnosis and high relapse rates fueling ongoing treatment demand. The expected launch of emerging therapies like Tezepelumab, APT-1011, IRL201104, and Vonoprazan will further propel market growth.

Why it matters

The eosinophilic esophagitis market is evolving rapidly due to a robust pipeline of innovative therapies addressing limitations of current options. Emerging treatments with novel mechanisms of action and improved delivery approaches are poised to transform the standard of care and unlock new growth opportunities.

The details

The US eosinophilic esophagitis market is expected to grow at a CAGR of 13.2% during 2026-2036, driven by the launch of TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators. Key pipeline candidates include Tezepelumab, APT-1011, IRL201104, and Vonoprazan, many of which have secured Orphan Drug Designation and Fast Track status, positioning them for accelerated development and market entry.

  • In Q3 2025, AstraZeneca indicated results from the CROSSING trial evaluating Tezepelumab in EoE are expected in H2 2026.
  • In May 2024, Ellodi Pharmaceuticals presented positive findings from the FLUTE-2 Phase III trial of APT-1011 at Digestive Disease Week.
  • In August 2025, Revolo Biotherapeutics announced plans to fast-track the clinical development of a sublingual tablet formulation of IRL201104.
  • In January 2026, Phathom Pharmaceuticals anticipates topline data in 2027 from its Phase II trial (pHalcon-EoE-201) evaluating Vonoprazan in EoE.
  • In November 2025, Eupraxia Pharmaceuticals announced positive 12-week and 36-week data from the RESOLVE trial of EP-104GI for EoE.

The players

AstraZeneca

A global biopharmaceutical company developing Tezepelumab, a novel monoclonal antibody targeting TSLP, for the treatment of eosinophilic esophagitis.

Ellodi Pharmaceuticals

A specialty pharmaceutical company advancing APT-1011, an innovative once-daily oral disintegrating tablet formulation of fluticasone propionate for EoE.

Revolo Biotherapeutics

A clinical-stage biopharmaceutical company developing IRL201104, a first-in-class peptide designed to re-establish immune balance in eosinophilic esophagitis.

Phathom Pharmaceuticals

A late-stage biopharmaceutical company evaluating its investigational therapy Vonoprazan for the treatment of eosinophilic esophagitis.

Eupraxia Pharmaceuticals

A clinical-stage specialty pharmaceutical company advancing EP-104GI, a once-yearly submucosal injection for eosinophilic esophagitis.

Got photos? Submit your photos here. ›

What they’re saying

“Emerging therapies that reduce dosing frequency or improve ease of administration may capture patients with adherence challenges or inadequate response to current options.”

— Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

The eosinophilic esophagitis market is poised for significant transformation as a robust pipeline of innovative therapies with novel mechanisms of action and improved delivery approaches are expected to reshape the standard of care and unlock new growth opportunities in the coming years.